Activation of glial cells as a response to A aggregation perpetuates neuronal injury through neuroinflammation (Morris et al., 2014)
a narrative review Katarzyna W
BPC-157 (Body Protection Compound-157) is a short, 15-amino acid synthetic peptide widely used in preclinical research to examine tissue-response patterns to experimentally induced stress or injury in controlled laboratory conditions
Gasparetto A, Corbucci GG, De Blasi RA, et al

Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology

There is also a rule that matters for anyone in competitive sport, since AOD 9604 is prohibited by the World Anti-Doping Agency, so athletes subject to testing need to be aware before they consider it